Clinical trials listed for ITP are a starting point for discussion with a healthcare professional. Be sure you understand all the implications of the proposed treatment by reading the informed consent very carefully and speaking with your doctor before enrolling in a clinical trial.
What are Clinical Trials?
Clinical Trials are controlled patient studies that must be performed before a new drug or treatment is approved by the Food and Drug Administration (FDA) in the United States and similar organizations in other countries. Clinical trials are also completed after a drug or treatment is approved to document the effectiveness of the treatment, or to gain approval to use the drug or therapy for a different disease or age group.
There are three main phases to clinical trials, completed in sequence. A Phase I study tests the safety and side effects of the drug. A Phase II study is initiated to determine the efficacy of the drug, to see if it works as anticipated. And, a Phase III study tests the efficacy of drug or treatment and documents the side effects in a large population of volunteers.
Finding a Clinical Trial
The best way to find the latest information on clinical trials is by visiting ClinicalTrials.gov, a database of privately and publicly funded clinical studies conducted around the world. Pharmaceutical companies and researchers update this site frequently to ensure it contains the most comprehensive and up-to-date clinical trial listings. The database features an easy-to-use search facility and detailed guidance for patients and industry.
Featured Clinical Trials
The Meza ITP clinical research Study is looking for participants who are 18 years or older, living with chronic primary immune thrombocytopenia (ITP), to take part in a clinical research study. This study is researching the safety and efficacy of an investigational study drug to reduce bleeding, improve quality of life, and increase blood platelet counts in individuals with ITP whose condition has not responded to two previous ITP treatments or has stopped responding. The study drug will be given as once-weekly injections in two eight-week dosing intervention periods, separated by a non-dosing period. To learn more about this study, visit https://www.mezaitp.com.
The LUNA 4 Study is looking at how an approved drug for immune thrombocytopenia, rilzabrutinib, could impact platelet counts and quality of life in adults who have not responded well to their first treatment (ex: steroids and/or IVIG). Safety will be monitored.
Participants must be:
- 18 years of age or older
- Diagnosed with primary ITP
- Have tried one first-line ITP therapy (such as corticosteroids, IVIg, or anti-D) which stopped working or required continuous use
Additional eligibility requirements apply.
This study has up to 4 periods:
- Screening: Individuals are evaluated for study fit
- Main treatment period (up to 28 weeks): All participants receive rilzabrutinib, a twice daily tablet — there is no placebo.
- Long-term extension (up to 28 additional weeks)
- Treatment-free follow-up (24 additional weeks)
Rilzabrutinib and all study-related tests are provided as part of the trial.
For more information, talk to your hematologist or visit:
https://www.sanofi.com/en/clinical-trials/nct07007962
List of Clinical Trials:
(Select from the list below)- Clinical Trials Actively Recruiting in the USA, Canada, and Internationally
- Completed Clinical Trials
- Clinical Trials for Other Platelet Disorders
Please contact PDSA if you find missing or incorrect information regarding any of the clinical trials listed.
